Rejuvenation

Rejuvenation: Leading the Future of Longevity

At 1mPossible, we are committed to shaping the future of rejuvenation and longevity. Our mission is to drive cutting-edge advancements in regenerative medicine and age reversal, with a global vision to lead the field.

At 1mPossible, we are dedicated to endorsing and supporting the most promising initiatives for success, with B4Tomorrow standing out as one of the most promising. It is an innovative company at the forefront of cellular rejuvenation, registered in the United States.

Meet the Team Behind B4Tomorrow
The talented individuals driving innovation in cellular rejuvenation. Together, we are pushing the boundaries of regenerative medicine and reshaping the future of longevity.

Cippitelli also serves as the CEO and Co-Founder of B4Tomorrow, alongside Delfina Gallardo, CSO, and Mateo Peyloubet, CFO, working together to push the boundaries of human potential.

We are also proud to have the expertise of Daniela López de Luise, an advisor at B4Tomorrow and a key member of 1mPossible. Additionally, we are fortunate to have Rodolfo Goya, a recognized leader in aging research, as an advisor to B4Tomorrow, where his insights help guide their innovative efforts in rejuvenation.

What B4Tomorrow Does
B4Tomorrow has developed a cutting-edge platform powered by OSKM (Oct4, Sox2, Klf4, and c-Myc) genes, which targets specific cells and proteins involved in aging-related diseases. This platform can effectively deliver a range of therapeutic cargoes without the need for surgery or anesthesia, addressing the safety limitations of currently developing solutions. Focused on cellular rejuvenation at the genetic level, B4Tomorrow is committed to advancing treatments for aging societies.

The company has achieved significant breakthroughs, including demonstrated improvements in cognitive performance in senile rats and enhanced reproductive performance in middle-aged rats through gene therapy applied to the reproductive hypothalamus. These preclinical successes highlight the versatility and potential of B4Tomorrow's platform for genetic age reversal and regenerative medicine.

Post-Money Valuation:
USD 6.250.000